Open, Randomized, 2-period, 2-sequence, Cross-over Relative Bioavailability Study to Investigate the Pharmacokinetics and to Assess the Bioequivalence of a Rivastigmine Test Patch Formulation 9.5 mg/24 h (Twice Weekly Patch) Compared to the Reference Exelon 9.5 mg/24 h (Once Daily Patch) Applied for 11 Days
Latest Information Update: 20 Sep 2019
At a glance
- Drugs Rivastigmine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors SocraTec R&D
- 18 Sep 2019 Status changed from recruiting to completed.
- 14 Sep 2018 New trial record